Article
No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy.
Antiviral research - 1 Dec 2011
Laufer N, Abusamra L, Bolcic F, Gun A, Rolón M J, Pérez H, Krolewiecki A, Salomón H, Quarleri J, Cahn P
Abstract excerpt
There are two new drugs approved and several in development for treatment of chronic HCV; among them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.